Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcut...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biogen
NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
NCT05304520 · Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02881567 · Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02568111 · Relapsing-Remitting Multiple Sclerosis (RRMS)
Research Site
Arezzo
Research Site
Bari
Research Site
Cagliari
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions